Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2011; 17(9): 1174-1179
Published online Mar 7, 2011. doi: 10.3748/wjg.v17.i9.1174
Published online Mar 7, 2011. doi: 10.3748/wjg.v17.i9.1174
Figure 4 Cumulative incidence of maintaining non-recurrent status in patients with anorectal stricture.
The cumulative incidence of fistula recurrence was 53.9%/5 years with infliximab (IFX) (n = 19) and 55.0%/5 years and 62.5%/10 years without IFX (n = 21), respectively.
- Citation: Uchino M, Ikeuchi H, Bando T, Matsuoka H, Takesue Y, Takahashi Y, Matsumoto T, Tomita N. Long-term efficacy of infliximab maintenance therapy for perianal Crohn’s disease. World J Gastroenterol 2011; 17(9): 1174-1179
- URL: https://www.wjgnet.com/1007-9327/full/v17/i9/1174.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i9.1174